Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bartlett who wrote (3187)	1/23/2000 12:58:00 PM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

Mark, all, I found this on a public forum for DMX: "Rumour du jour---Early next week, Dr. Khune of WF10 fame is to be making an announcement- re. trials. Apparently, all placebo patients in their current study will be taken off and given the drug due to huge success rates of no hospitalization days for the control group. Heard the the words "fast tracked" once again. It would make sense as it would save governments and insurance companies large $$$. Take it for what it's worth." ... I can't speak to these rumours directly, but, I'm again reminded of the dramatic Vanderbilt results in phase II. The comment about no hospitalization days in the quote above is exactly what they found in that Vanderbilt trial. Personally, I would be suprised if they don't find similar dramatic results in a similar trial of a larger group. Also, to me the investment of precious cash into another company while coming out with your own first product as a junior bio tech is a very unusual move. Strong public validation of WF10 early would again validate my faith in Dimethaid and the decisions it is making. One thing I didn't notice being discussed from the conference call, was Rebecca's comments about manufacturing. She talked about the volume committments to partners and the logistics that Celebrex and Vioxx faced in supplying the billion dollar plus demand for each last year. Our hugely factual CEO is publicly comparing her Pennsaid manufacturing requirements with billion dollar drugs. I've always felt that Pennsaid would break the $200 million Canadian worldwide sales number (at the Dimethaid level) that I projected in my models. Thats an effort to assess results with a high probability of success given limited information. Thats always translated into a $35-45 share price depending on assumptions. Market sales would be in the order of $450 million US based on a 70-30 split of street price revenues. If Pennsaid does a billion, I should be able to get that new pair of shoes!